Abstract | OBJECTIVES: METHODS: Among 467 patients with renal cell carcinoma treated between April 1984 and March 1993, 191 were treated with SMANCS dissolved in a lipid contrast medium (a 3:2 mixture of Lipiodol F and Lipiodol Ultrafluid; Lpd). Selective arterial infusion of SMANCS/Lpd was performed at a dose of 1.0 or 1. 5 mg/mL. The infusion was repeated at intervals of about 2 weeks or longer, but the doses and the total number of infusions varied among patients, according to results of computed tomography analysis. RESULTS: Statistical analysis was performed for 415 patients who met the criteria of this study. Twenty-six surgical patients with metastases who underwent infusion therapy of SMANCS/Lpd for primary lesions showed 3 and 5-year survival rates of 23.0% and 12.8%, respectively; the rates were 19.3% and 9.7% in 31 patients who did not receive SMANCS infusion therapy. In 125 surgical patients without metastases who underwent SMANCS/Lpd infusion, the 5 and 10-year survival rates were 83.0% and 75.2%, respectively, whereas rates of 84.6% and 78.9% were observed in 199 surgical patients whose median tumor size was significantly smaller, however, than the SMANCS/Lpd infusion group. The maximal tumor diameter at the beginning of treatment was significantly larger (mean diameter 70.8 mm) in the SMANCS/Lpd infusion group than in the noninfusion group (59.1 mm). The survival rate was statistically better for patients with tumors of 100 mm diameter or larger in the SMANCS/Lpd infusion group (P <0.05): 5 and 10-year survival rates were 70.4% and 61.6%, respectively, for the infusion group and 64.6% and 50.9% for the group receiving no drug. In patients with larger tumor (greater than 110 mm), the survival rate at 13 years was 75% in the SMANCS/Lpd infusion group and 0% in the surgery group. CONCLUSIONS:
|
Authors | K Tsuchiya, T Uchida, M Kobayashi, H Maeda, T Konno, H Yamanaka |
Journal | Urology
(Urology)
Vol. 55
Issue 4
Pg. 495-500
(Apr 2000)
ISSN: 1527-9995 [Electronic] United States |
PMID | 10736490
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Maleic Anhydrides
- Polystyrenes
- poly(maleic acid-styrene)neocarzinostatin
- Iodized Oil
- Zinostatin
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Carcinoma, Renal Cell
(drug therapy, mortality, pathology, surgery)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Infusions, Intra-Arterial
- Iodized Oil
(administration & dosage, adverse effects)
- Kidney Neoplasms
(drug therapy, mortality, pathology, surgery)
- Male
- Maleic Anhydrides
(administration & dosage, adverse effects)
- Middle Aged
- Neoadjuvant Therapy
- Neoplasm Staging
- Polystyrenes
(administration & dosage, adverse effects)
- Survival Rate
- Tomography, X-Ray Computed
- Treatment Outcome
- Zinostatin
(administration & dosage, adverse effects, analogs & derivatives)
|